Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells

Abstract

The Raf/MEK/ERK kinase cascade is pivotal in transmitting signals from membrane receptors to transcription factors that control gene expression culminating in the regulation of cell cycle progression. This cascade can prevent cell death through ERK2 and p90Rsk activation and phosphorylation of apoptotic and cell cycle regulatory proteins. The PI3K/Akt kinase cascade also controls apoptosis and can phosphorylate many apoptotic and cell cycle regulatory proteins. These pathways are interwoven as Akt can phosphorylate Raf and result in its inactivation, and Raf can be required for the antiapoptotic effects of Akt. In this study, the effects of activated Raf (Raf-1, A-Raf and B-Raf) and PI3K/Akt proteins on abrogation of cytokine dependence in FL5.12 hematopoietic cells were examined. Activated Raf, PI3K or Akt expression, by themselves, did not readily relieve cytokine dependence. The presence of activated Raf and PI3K/Akt increased the isolation of factor-independent cells from 400- to 2500-fold depending upon the particular combination examined. The individual effects of activated Raf and Akt on proliferation, apoptosis and autocrine growth factor synthesis were further examined with hormone-inducible constructs (ΔRaf-1:AR and ΔAkt:ER*(Myr+). Activation of either Raf or Akt hindered cell death; however, both proliferation and maximal synthesis of autocrine cytokines were dependent upon activation of both signaling pathways. The effects of small molecular weight inhibitors on DNA synthesis and cytokine gene expression were also examined. The PI3K inhibitor, LY294002, inhibited growth and cytokine gene expression. This effect could be synergistically increased by addition of the MEK inhibitor UO126. These cells will be useful in elucidating the interactions between Raf/MEK/ERK and PI3K/Akt cascades in proliferation, apoptosis, and leukemogenesis, as well as evaluating the efficacy of signal transduction inhibitors that target these cascades.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Blalock WL, Moye PW, Chang F, Pearce M, Steelman LS, McMahon M and McCubrey JA . (2000b). Leukemia, 14, 1080–1096.

  • Blalock WL, Pearce M, Chang F, Lee J, Pohnert S, Burrows C, Steelman LS, Franklin RA, McMahon M and McCubrey J . (2001). Leukemia, 15, 794–807.

  • Blalock WL, Pearce M, Steelman LS, Franklin RA, McCarthy SA, Cherwinski H, McMahon M and McCubrey JA . (2000a). Oncogene, 19, 526–536.

  • Blalock WL, Weinstein-Oppenheimer C, Chang F, Hoyle PE, Wang XY, Algate PA, Franklin RA, Oberhaus SM, Steelman LS and McCubrey JA . (1999). Leukemia, 13, 1109–1166.

  • Bosch E, Cherwinski H, Peterson D and McMahon M . (1997). Oncogene, 11, 1021–1034.

  • Carroll MP and May WS . (1994). J. Biol. Chem., 269, 1249–1256.

  • Chang F and McCubrey JA . (2001). Oncogene, 20, 4353–4364.

  • Chang F, Steelman LS and McCubrey JA . (2002). Cell Cycle, 1, 220–227.

  • Chaudhary A, King WG, Mattaliano MD, Frost JA, Diaz B, Morrison DK, Cobb MH, Marshall MS and Brugge JS . (2000). Curr. Biol., 10, 551–554.

  • Clark SS, McLaughin J, Timmons M, Pendergast AM, Ben-Neriah Y, Dow LW, Crist W, Rovera G, Smith SD and Witte ON . (1988). Science, 239, 775–777.

  • Craddock BL and Welham MJ . (1997). J. Biol. Chem., 272, 29281–29289.

  • Dhillon AS, Meikle S, Yazici Z, Eulitz M and Kolch W . (2002a). EMBO J., 21, 64–71.

  • Dhillon AS, Pollock C, Steen H, Shaw PE, Mischak H and Kolch W . (2002b). Mol. Cell. Biol., 22, 3237–3246.

  • Duronio V, Scheid MP and Ettinger S . (1998). Cell. Signal. 10, 233–239.

  • Eychene A, Dusanter-Fourt I, Barnier JV, Papin C, Charon M, Gisselbrecht S and Calothy G . (1995). Oncogene, 10, 1159–1165.

  • Gelfanov VM, Burgess GS, Litz-Jackson S, King AJ, Marshall MS, Nakshatri H and Boswell HS . (2001). Blood, 15, 2508–2517.

  • Guan K, Figueroa C, Brtva TR, Zhu T, Taylor J, Barber TD and Vojtek AB . (2000). J. Biol. Chem., 275, 27354–27359.

  • Hoyle PE, Moye PW, Steelman LS, Blalock WL, Franklin RA, Pearce M, Cherwinski H, Bosch E, McMahon M and McCubrey JA . (2000). Leukemia, 14, 642–656.

  • Kaleko M, Rutter WJ and Miller AD . (1990). Mol. Cell. Biol., 10, 464–473.

  • Khosravi-Far R, White MA, Westwick JK, Solski PA, Chrzanowska-Wodnicka M, Van Aelst L, Wigler MH and Der CJ . (1996). Mol. Cell. Biol., 16, 3923–3933.

  • Kohn D, Takeuchi F and Roth RA . (1996). J. Biol. Chem., 271, 21920–21926.

  • Kubota Y, Angelotti T, Niederfellner G, Herbst R and Ullrich A . (1998). Cell Growth Differ., 9, 247–256.

  • Lloyd AC, Obermuller F, Staddon S, Barth CF, McMahon M and Land H . (1997). Genes Dev., 11, 663–677.

  • Majewski M, Nieborowska-Skorska M, Salomoni P, Slupianek A, Reiss K, Trotta R, Calabretta B and Skorski T . (1999). Cancer Res., 59, 2815–2819.

  • Marais R, Light Y, Paterson HF and Marshall CJ . (1995). EMBO J., 14, 3136–3145.

  • Marshall M . (1995). Mol. Reprod. Dev., 42, 493–499.

  • McCubrey JA, Blalock WL, Chang F, Steelman LS, Pohnert SC, Navolanic PM, Shelton JG, Hoyle PE, Moye PW, Oberhaus SM, White MK, Lee JT and Franklin RA (2001d). Cell Cycle Checkpoints and Cancer. Blagosklonny M. (ed). Landes Bioscience Press: Austin, TX, pp. 17–51.

    Google Scholar 

  • McCubrey J, Holland G, McKearn J and Risser R . (1989). Oncogene Res., 4, 97–109.

  • McCubrey JA, Lee JT, Steelman LS, Blalock WL, Moye PW, Chang F, Pearce M, Shelton JG, White MK, Franklin RA and Pohnert SC . (2001a). Cancer Detect. Prevent., 25, 375–393.

  • McCubrey JA, May WS, Duronio V and Mufson A . (2000a). Leukemia, 14, 9–21.

  • McCubrey JA, Steelman LS, Blalock WL, Lee JT, Moye PW, Chang F, Pearce M, Shelton JG, White MK, Franklin RA and Pohnert SC . (2001b). Adv. Enzyme Regul., 41, 289–323.

  • McCubrey JA, Steelman LS, Hoyle PE, Blalock WL, Weinstein-Oppenheimer C, Franklin RA, Cherwinski H, Bosch E and McMahon M . (1998). Leukemia, 12, 1903–1929.

  • McCubrey JA, Steelman LS, Mayo MW, Algate PA, Dellow RA and Kaleko M . (1991). Blood, 78, 921–929.

  • McCubrey JA, Steelman LS, Moye PW, Hoyle PE, Weinstein-Oppenheimer C, Chang F, Pierce M, White MK, Franklin R and Blalock WL . (2000b). Adv. Enzyme Regul., 40, 305–337.

  • McCubrey JA, Wang XY, Algate PA, Blalock WL and Steelman LS . (2001c). Cell Cycle Checkpoints and Cancer. Blagosklonny M. (ed) Landes Bioscience Press Austin, TX, pp. 1–16.

    Google Scholar 

  • McIlroy J, Chen D, Wjasow C, Michaeli T and Backer JM . (1997). Mol. Cell. Biol. 17, 248–255.

  • McKearn JP, McCubrey JA and Fagg B . (1985). Proc. Natl. Acad. Sci. USA, 85, 7414–7418.

  • McMahon M . (2001). Methods Enzymol., 332, 401–417.

  • Minshall C, Arkins S, Freund GG and Kelly KW . (1996). J. Immunol., 156, 939–947.

  • Mischak H, Seitz T, Janosch P, Eulitz M, Steen H, Schellerer M, Philipp A and Kolch W . (1996). Mol. Cell. Biol., 16, 5409–5418.

  • Mizra A, Kohn AD, Roth RA and McMahon . (2000). Cell Growth Diff., 11, 279–292.

  • Mizutani S, Inouye K, Koide K and Kaziro Y (2001). FEBS Lett., 507, 295–298.

  • Morgenstern JP and Land H . (1990). Nucleic Acids Res., 18, 3587–3596.

  • Moye PW, Blalock WL, Hoyle PE, Chang F, Franklin RA, Weinstein-Oppenheimer C, Pearce M, Steelman L, McMahon M and McCubrey JA . (2000). Leukemia, 14, 1060–1079.

  • Rapp UR, Huleihel M, Pawson T, Linnoila I, Minna JD, Heidecker G, Cleveland JL, Beck T, Forchhammer J and Storm SM . (1988). Lung Cancer, 4, 162–167.

  • Rodriguez-Viciana P, Marte BM, Warne PH and Downward J . (1996). Philos. Trans. Roy. Soc. London Series B: Biol. Sci., 351, 225–231.

  • Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD and Downward J . (1996). EMBO J., 15, 2442–2451.

  • Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A and Downward J . (1997). Cell, 89, 457–467.

  • Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, Reid K, Moelling K, Yancopoulos GD and Glass DJ . (1999). Science, 286, 1738–1741.

  • Samuels ML, Weber MJ, Bishop JM and McMahon M (1993). Mol. Cell. Biol., 13, 6241–6252.

  • Scheid MP and Duronio V . (1998). Proc. Natl. Acad. Sci. USA, 95, 7439–7444.

  • Scheid MP and Woodgett JR . (2001). Nat. Rev. Mol. Cell. Biol., 2, 760–768.

  • Storm SM and Rapp UR . (1993). Toxicol. Lett., 67, 201–210.

  • Sutor SL, Vroman BT, Armstrong EA, Abraham RT and Karnitz LM . (1999). J. Biol. Chem., 274, 7002–7010.

  • Tan Y, Ruan H, Demeter MR and Comb MJ . (1999). J. Biol. Chem., 274, 34859–34867.

  • Vanhaesebroeck B, Leevers SJ, Panayotou G and Waterfield MD . (1997). Trends Biochem. Sci., 22, 267–272.

  • von Gise A, Lorenz P, Wellbrock C, Hemmings B, Berberich-Siebelt F, Rapp UR and Troppmair J . (2001). Mol. Cell. Biol., 21, 2324–2336.

  • Weber CK, Slupsky JR, Kalmes HA and Rapp UR . (2001). Cancer Res., 61, 3595–3598.

  • Weinstein-Oppenheimer CR, Blalock WL, Steelman LS, Chang F and McCubrey JA . (2000b). Pharmacol. Therap., 88, 230–279.

  • Weinstein-Oppenheimer C, Steelman LS, Algate PA, Blalock WL, Burrows C, Hoyle PE, Lee JT, Moye PW, Shelton JG, Franklin RA and McCubrey JA . (2000a). Leukemia, 14, 1921–1938.

  • Wick MJ, Dong LQ, Riojas RA, Ramos FJ and Liu F . (2000). J. Biol. Chem., 275, 40400–40406.

  • Williams MR, Arthur JS, Balendran A, van der Kaay J, Poli V, Cohen P and Alessi DR . (2000). Curr. Biol., 10, 439–448.

  • Woods D, Parry D, Cherwinski H, Bosch E, Lees E and McMahon M . (1997). Mol. Cell. Biol., 17, 5598–5611.

  • Xing J, Ginty DD and Greenberg ME . (1996). Science, 273, 959–963.

  • Yan J, Roy S, Apolloni A, Lane A and Hancock JF . (1998). J. Biol. Chem., 273, 24052–24056.

  • Zhang BH, Tang E, Zhu T, Greenberg M, Vojtek A and Guan KL . (2001). J. Biol. Chem., 276, 31620–31626.

  • Zhou X, Liu Y, Payne G, Lutz RJ and Chittenden T . (2000). J. Biol. Chem., 275, 25046–25051.

  • Zimmermann S and Moelling K . (1999). Science, 286, 1741–1744.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to James A McCubrey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shelton, J., Steelman, L., Lee, J. et al. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene 22, 2478–2492 (2003). https://doi.org/10.1038/sj.onc.1206321

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206321

Keywords

This article is cited by

Search

Quick links